CD8A and plasma cell myeloma: In addition, as the major effector of antitumor immunity, CD8+ CTLs eliminate cancer cells by secreting granzyme B (GZB).[20] Thus, we examined CTL activity by measuring GZB release in bone marrow aspirates isolated from healthy donors and myeloma patients before or after treatment.